Glenmark gets USFDA nod for generic version of acne treatment gel
Glenmark Pharmaceuticals on Friday said it has received final approval from the US health regulator for its generic version of BenzaClin gel used in15-03-2019
15-03-2019
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals receives ANDA approval for Clindamycin and Benzoyl Peroxide Gel, 1%/5% With reference to the subject mentioned above, kindly find attached media release which is self explanatory.15-03-2019
Novartis, Gilead veteran named Glenmark's innovative business CEO
Riva's appointment as CEO of Glenmark's innovation business is effective from April 2.06-03-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals Announces Appointment of Alessandro Riva as CEO of its New Innovation Company06-03-2019
Company news: Glenmark Pharmaceuticals
Glenmark Pharmaceuticals on Tuesday said it has received final approval from the US health regulator for Telmisartan and Hydrochlorothiazide tablets,05-03-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Telmisartan and Hydrochlorothiazide Tablets USP, 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg05-03-2019
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals Announces Presentation of New Subtype Analysis of GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the American Academy of Dermatology Annual Meeting04-03-2019
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals Announces Results from New Analysis of Pooled Data on Ryaltris(tm), an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting.26-02-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals Announces Results from New Analysis of Pooled Data on Ryaltris(tm), an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting.26-02-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris(tm), an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual MeetingGlenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris(tm), an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting20-02-2019